Mesenchymal stromal cells (MSC) are widely used, isolated from a variety of tissues 19' and increasingly adopted for cell therapy, but the identity of these cells is poorly 20' defined and commonalities between MSC from different tissues sources is 21' controversial. Here we undertook a comprehensive review of all public MSC
Introduction

37'
Adult tissues maintain the capacity to be replenished as part of the normal processes 38' of homeostasis and repair. The adult stem cell hypothesis proposes that multipotent 39' cells resident in tissues are the source of this cellular renewal, and expand in 40' response to tissue injury. MSC were first isolated from bone marrow, where these 41' occupy an important stem cell niche required for reconstitution of bone and the 42' stromal compartments of marrow, and also play a supportive role in haematopoiesis 43'
(1, 2). Subsequently adult stromal progenitors have been isolated and cultured from 44' most organs including placenta, heart, adipose tissue and kidneys although the 45' identity of these cells remains controversial (reviewed by (3, 4) ). Specifically the 46' question of how similar cells isolated outside the bone marrow niche are is 47' unresolved, nor whether these could be considered bona fide MSC, or indeed 48' challengingly, whether MSC isolated from different tissues share any phenotypic or 49' molecular characteristics at all (3). In this light various cells described as MSC (5). It has been variously argued that MSC isolated from most stromal tissues are 53' derived from perivascular progenitors (6), or recruited from the bone marrow to distal 54' tissue sites (7) , or that resident stromal progenitors from different tissues must have 55' tissue-restricted phenotypes.
56'
The question of ontogeny aside, there is little consensus on whether MSC from 57' differing tissue sources share common functional attributes. Most human studies 58' have been conducted on very small numbers of donors, so it is difficult to dissect 59' donor-donor heterogeneity from source heterogeneity. Donor-donor variation is a 60' Rohart'et'al, 'The'MSC'Signature' 4' major contributor to differences in MSC growth and differentiation capacity, and 61' clonal variation is evident even when derived from the same bone marrow (8, 9) .
62'
Consequently there is little agreement in the literature on definitive molecular or 63' cellular phenotypes of human cultured MSC, whether from bone marrow or other 64' sources.
65'
The lack of definitive markers for human MSC is a major barrier to understanding 66' genuine similarities, or resolving differences between various cell sources or 67' subsets. Modern molecular classification tools are needed for the characterisation of 68' MSC ex vivo and in vivo. Here we describe a sophisticated integrative transcriptome 69' analysis of public MSC datasets to assess how similar these cells are, and describe 70' the major classes of MSC captured in the literature to date.
71'
72'
Results
73'
A 16-gene MSC signature defines an overarching MSC phenotype. 74' To address whether MSC shared a common molecular phenotype that could 75' distinguish them from other stromal or progenitor cells, we systematically reviewed 76' all of the publicly available transcriptome data for presumed MSC, identifying 120 77' potential datasets that were derived from a wide variety of tissues and age groups,
78'
but 35/120 datasets failed our QC criteria for data quality and were excluded from 79' the study. We assessed the accompanying phenotypic data of the remaining 85 80' datasets carefully (Supplementary Tables S1-S5) for immunophenotype and ex vivo 81' differentiation, as determined by the International Society for Cellular Therapy (10). A
82'
'gold standard' sample set was assembled, consisting of 125 MSC samples from 16 83' Rohart'et'al, 'The'MSC'Signature' 5' independently derived datasets. The 'Gold standard' MSC were primarily derived 84' from bone marrow, but also included a variety of adult, neonatal and fetal stromal 85' sources, and these were compared to 510 non-MSC samples from primary human 86' tissues, including cultured fibroblasts, haematopoietic cells and pluripotent stem cell 87' lines ( Supplementary Table S1 , S2).
88'
We derived a novel cross-study framework to test whether we could find similarities 89' between the MSC in our training set despite tissue, platform or laboratory 90' differences. Our approach, described in Figure 1A , included a cross-platform 91' normalisation step (11), and a modified multivariate discriminant analysis that
92'
included steps to evaluate the stability of gene selection when datasets were
93'
subsampled as well as steps to evaluate the informativeness of the variables that 94' contributed to each component ( Figure 1B, Supplementary Figure S1 ).
95'
This identified 16 genes ( Figure 1C ) that collectively formed a 'signature', which 96' across 4 components grouped bone-marrow derived MSC with MSC from other 97' sources, and provided a high degree of discrimination between MSC and non-MSC
98'
cell types ( Figure 1D, Supplementary Figure S1 ). The accuracy of the signature 99' (Table 1) the benefit of including more genes. Each dot is a gene set, ordered along the x-axis 107' Rohart'et'al, 'The'MSC'Signature' 6' by decreasing stability (frequency of selection). The y-axis represents the -log 10 (P-
108'
value) of a one tailed t-test at level a=1% indicating the improvement in classification 109' accuracy; Component 1 genes are indicated in green, component 2 genes in blue,
110'
component 3 genes in brown and component 4 genes in grey.
111'
C) The 16-gene MSC signature colour coded to the component that it contributes to 112' (as per 1B). Gene ID is given as HUGO symbol and ENSEMBL gene ID; 'C' is immune-markers), or was an output of our statistical model with genes selected in an 132'
unbiased manner (cf Figure 1A) .
133'
134'
The signature is more informative than a literature-derived set of MSC 135' markers.
136'
The International Society for Cellular Therapy (10) had identified a set of commonly 137' used markers to immunophenotype MSC ( Supplementary Table S6 ). These markers 138' did cluster MSC samples from the training set together on a MDS plot ( Figure 1E ), shared with stromal fibroblasts, endothelial progenitors and hematopoietic cells. The
145'
variable expression of these markers (Supplementary Figure S2 ) may also explain 146'
the variability of marker use reported by the wider MSC research community.
147'
148'
The MSC signature genes are essential to healthy mesenchymal development 149' and function.
150'
To assess possible functional relationships between MSC signature genes, we used
151'
a curated set of protein-protein interactions from the BioGrid database using the 152'
genes selected from component 1 that showed a high discriminating power between
153'
MSC and non-MSC. These formed a network of 43 interacting proteins (Figure 2A ).
154'
A high proportion of these (30/43) are represented in Mendelian disorders of models ( Supplementary Table S7 ). These included the paired-related homeobox-1 158'
(PRRX1), a transcription factor important for early embryonic skeletal and facial 159' development, and with a de novo mutation spectrum in the embryonic ABI3BP are associated with increased risk of osteochondropathy (16) . and discriminates between differentiating or related adult stem cell types.
169'
A) An extended protein-protein network diagram of the Rohart MSC signature genes grey) if its prediction score or its CI overlapped the uncertainty region. represent the CI boundaries.
189'
190'
The extended network included several previously described MSC immune-markers.
191'
ITGA11 for example was a member of the core signature, and although it is not a 192' commonly adopted MSC marker, ITGA11 has been used to prospectively enrich
193'
MSC from bone marrow with enhanced colony forming capacity (17) The majority of public microarray datasets available to us had limited phenotypic
231'
data available, so these were not used to derive our MSC signature. Nevertheless
232'
we annotated each of these samples as presumptive MSC (213 samples an 'unknown' category (579 samples) prior to testing these with the signature.
237'
Despite the lack of phenotypic information associated with these datasets, the 238' agreement between publication status and our classification was high, with only 9
239'
presumptive MSC scored as non-MSC (4.2%). Five percent of the presumptive non-
240'
MSC (27/499) were misclassified by the signature as MSC, and around half of these 241'
(>13) were neonatal or fetal dermal fibroblasts ( Supplementary Table S4 , S5),
242'
although these formed the cluster with the greatest distance from the bone-marrow
243'
MSC. Fibroblasts from other sources were not classified as MSC, furthermore, the 244' signature could discriminate between MSC and differentiating cultures. Figure 2B 245'
demonstrates loss of the MSC score during chondrogenic differentiation with the 246'
addition of TGFβ3 (Dataset 6119 (32)) and this pattern was recapitulated for cells
247'
differentiating to mineralising bone or to adipose-like cells or when undergoing
248'
reprogramming of an adipose-tissue derived iPSC (Supplementary Figure S3 ).
249'
250' cells in skeletal and smooth muscle were classified as MSC ( Figure 2C ). In contrast,
Comparison of MSC and adult stem/progenitor cell types
256'
the majority of cells derived from a perivascular location (and confirmed as such with
257'
tissue imaging) were not classified as MSC ( Figure 2D ). The limbal cell niche hosts
258'
both limbal epithelial and stromal progenitors (34), and the stromal progenitors are 259' also classified as MSC by our tool (Dataset 6450).
260'
261' Rohart'et'al,' The'MSC'Signature'
13'
Transcription factor expression drives tissue clustering of MSC but is 262' confounded by gender and MHC-1 haplotype.
263'
The capacity to group MSC-like cells is consistent with the general assumption that
264'
MSC from different tissue share some common molecular properties, but is not 265' otherwise able to assess functional differences between cells isolated from different 266' sources.
267'
268'
When we examined the clustering of MSC by the 16-gene signature (Figure 3) , we
269'
observed that the majority of bone marrow MSC clustered together, and these were 270' more similar to fetal blood or fetal liver derived cells than MSC isolated from adipose
271'
tissue, placenta or skin. We therefore examined more broadly the genes that were P<0.01, Supplementary Table S8 ). Gene ontology analysis revealed higher Table S8 and S9), which suggests donor remains the largest contributor to variation.
299'
The HLA isotypes were generally, but not exclusively, expressed at lower levels in
300'
bone marrow MSC. Estrogen and progesterone receptors, and a network of
301'
associated target genes were also significantly different between tissue sources
302'
( Supplementary Table S9 ), and this may reflect a gender bias in tissue sampling;
303'
although the gender of the donors was not available for a majority of samples, some 304' tissues (such as decidual sources) will be entirely female in origin. Further molecular
305'
sub-classifications of MSC will therefore much larger studies that address specific 306' clinical or differentiation properties of the cells, and must also consider ascertainment
307'
biases that may introduce confounding variables such as HLA subtypes or gender.
308'
309' Rohart'et'al,' The'MSC'Signature'
15'
All together we curated more than 120 MSC-related gene expression datasets in the Our approach highlights the potential robustness of biological signatures when 335' combining data from many different sources, where experimental variables such as 336' platform or batch can be reduced ( Figure S4 ). The methods we used for derivation of 337' a common MSC classifier could be applied to the meta-analysis of any cell subset or
338'
phenotype where sufficient samples can be drawn from public expression 339' databases. The bulk of the expression data available to us was generated on 340'
microarray platforms, and this brings some caveats. VCAM1, CD73 and CD105 were 341' part of the extended PPI network but were not included in our core signature. This
342'
may be a consequence of cross-platform meta-analysis, as not all MSC genes will be 343'
represented with a quality probe on all of the array platforms, or may reflect a lack of 344' specificity when MSC are compared to a wide atlas of other cell types, or may reflect 345' a high variability in mRNA expression from donor to donor or across tissue sources.
346'
Nevertheless the inclusion of these known MSC markers in our extended network,
347'
and demonstration of the high connectivity between VCAM1 and our core signature,
348'
together with the high level of genetic perturbation impacting on mesenchymal 349' tissues in this network, provided us with confidence in the biological relevance of our 350' core members.
351'
352'
The question of what is an MSC, and whether these are a distinct stem cell
353'
population recruited from the bone marrow, as suggested by mouse studies of are resident progenitor populations specific to each organ cannot be resolved in the 357' current study. However a particular strength of this signature was the sub-grouping
358'
MSC into distinct clusters, including a predominantly bone-marrow cluster. The
359'
clustering of MSC, perivascular cells and fibroblasts as distinct cell types is
360'
consistent with the idea that these may represent a continuum along a stromal stem 361' cell hierarchy.
362'
363'
The signature itself is obviously dependent on the quality of the MSC used in the datasets, we anticipate that functional classification of MSC subtypes will improve as 369'
newer sampling methods provide the means to identify and replicate these cells. We
370'
expect that further refinements in the isolation or culture of purer MSC or more
371'
precisely defined functional subsets will also result in further refinements of this 372' signature.
373'
374'
In summary, we set out to systematically review the current state of play in MSC
375'
biology using a meta-analysis of transcriptome studies, and in doing so were able intractable questions of MSC identity, ontogenic relationships and function.
387'
388'
Materials and Methods
389'
Additional details are provided in the Extended Experimental Procedures
390'
Design of test and training datasets.
391'
We first carefully curated human MSC expression profiling experiments from GEO
392'
and ArrayExpress, evaluating each dataset to ensure samples met our criteria for 393'
primary data quality and a minimal MSC phenotype of CD105 + , CD73 + and CD45 -,
394'
with demonstrated differentiation to multiple mesenchymal lineages (see extended 395' methods).
396'
A review of public gene expression databases GEO and ArrayExpress identified 120 conditions. All primary data are available from the Stemformatics stem cell resource.
414'
The underlying code for the statistical test is available as BootsPLS in the CRAN
415'
repository, and we have also made available the d3 code for the interactive MSC 
MSC or non-MSC class
421'
All microarray experiments analyzed in this paper were pre-processed using the R
422'
programming language (R Core Team, 2012) . This involved a background correction
423'
of the raw data, a log 2 and a YuGene transformation (11) which minimised batch 424' effects caused by different microarray platforms (Supplementary Figure S4) . The
425'
resulting data were then mapped to Ensembl gene ID to provide a common set of contribution to classification accuracy of all the genes selected at least twice over the
433'
200 replications (Figure 1, Supplementary Figure S1 ). This reduced the signature to 434'
16 key genes.
435'
436'
The final statistical model is fitted with the 16 signature genes on the training set and Table S1 . Datasets in the training set; accompanies Figure 1 and methods. Table S3 . Datasets that contributed to the testing set: Accompanies Figure 2 . Table S6 . Markers used in the common MSC immunophenotyping panel.
591'
Accompanies Figure 1 and Table 1. 592 '   Table S7 . Members of the MSC signature network, seeded from component 1 genes
593'
and first-order interaction partners (BioGRID). Column 1 provides information on 
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